Reuters logo
BRIEF-Aptevo Therapeutics says next generation ADAPTIR bispecific antibody candidates show potent immune activation
2017年4月3日 / 下午1点26分 / 6 个月前

BRIEF-Aptevo Therapeutics says next generation ADAPTIR bispecific antibody candidates show potent immune activation

April 3 (Reuters) - Aptevo Therapeutics Inc

* Aptevo therapeutics’ next generation adaptir™ bispecific antibody candidates show potent immune activation

* Aptevo -new data highlight potent in vitro and in vivo activity of apvo436 and apvo437 at inducing rtcc in preclinical models of acute myelogenous leukemia Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below